Sun, FangMu, ChenglinKwok, Hang FaiXu, JiyuanWu, YingliangLiu, WanhongSabatier, Jean-MarcAnnweiler, CédricLi, XugangCao, ZhijianXie, Yingqiu2021-12-212021-12-212021Sun, F., Mu, C., Kwok, H. F., Xu, J., Wu, Y., Liu, W., Sabatier, J. M., Annweiler, C., Li, X., Cao, Z., & Xie, Y. (2021). Capivasertib restricts SARS-CoV-2 cellular entry: a potential clinical application for COVID-19. International Journal of Biological Sciences, 17(9), 2348–2355. https://doi.org/10.7150/ijbs.57810http://nur.nu.edu.kz/handle/123456789/5943Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to more than 150 million infections and about 3.1 million deaths up to date. Currently, drugs screened are urgently aiming to block the infection of SARS-CoV-2. Here, we explored the interaction networks of kinase and COVID-19 crosstalk, and identified phosphoinositide 3-kinase (PI3K)/AKT pathway as the most important kinase signal pathway involving COVID-19. Further, we found a PI3K/AKT signal pathway inhibitor capivasertib restricted the entry of SARS-CoV-2 into cells under non-cytotoxic concentrations. Lastly, the signal axis PI3K/AKT/FYVE finger-containing phosphoinositide kinase (PIKfyve)/PtdIns(3,5)P2 was revealed to play a key role during the cellular entry of viruses including SARS-CoV-2, possibly providing potential antiviral targets. Altogether, our study suggests that the PI3K/AKT kinase inhibitor drugs may be a promising anti-SARS-CoV-2 strategy for clinical application, especially for managing cancer patients with COVID-19 in the pandemic eraenAttribution-NonCommercial-ShareAlike 3.0 United StatesType of access: Open AccessCOVID-19SARS-CoV-2AKT inhibitorcapivasertibantiviral activityArticle